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Abstract. 
 
We studied effects of PPARα agonists clofibric acid and gemfibrozil on cell 
growth and functions of immortalized human extravillous trophoblast cells.  Levels 
of DNA and protein gradually increased during incubation for 4 days.  Gemfibrozil 
(> 0.25 mM) and clofibric acid (2.5 mM) suppressed the rate of increase in DNA and 
protein.  Specific activities of fatty acyl-CoA oxidase and catalase were increased to 
about 1.2 ~ 2.0 times the control value by 0.05 mM gemfibrozil and 1.0 and 2.5 mM 
clofibric acid after incubation for 3 days.  Acid phosphatase activity showed a small 
increase in response to both agents, but esterase activity changed little.  The 
secretion of progesterone from the cells into the medium was increased by 0.25 mM 
gemfibrozil and 1.0 and 2.5 mM clofibric acid after incubation for 3 days, but that of 
human chorionic gonadotropin (hCG) was decreased by 0.35 mM gemfibrozil and 2.5 
mM clofibric acid.  The specific activity of lactate dehydrogenase in the cells was 
hardly changed at all after incubation for 3 days. 
 These results suggest that gemfibrozil and clofibric acid inhibit the 
proliferation of trophoblast cells.  Cell metabolism is probably affected by both 
agents.  The two agents may down-regulate hCG and up-regulate progesterone 
secretions.  
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1. Introduction  
 
Although reports about the peroxisomes of rat liver are abundant [1-16], much 
less is known about those of other rat organs [17, 18].  Moreover, there are few 
reports about peroxisomes of human liver [2, 3, 5, 6, 8-10, 14, 19], and very few 
about those of other human organs [20-22].  In regard to the effect of 
PPARα agonist on peroxisomal enzymes and proliferation, there are many reports 
about rat liver [1-16].  In human liver cells, some reports revealed an increase in 
peroxisomal enzyme activity caused by PPARα agonist [5, 6, 10, 12, 19], while 
others found no effect [2, 3, 8, 9, 14].  In all organs except the liver, the effects of 
PPARα agonist on peroxisomes are little reported in rats [17], and even less so in 
humans [21]. 
Fibric acid derivatives are not only PPARα agonists in rodents, but also 
hypolipidemic agents.  Clofibrate, at least, is thought to suppress the synthesis of 
cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA 
reductase), the rate-limiting enzyme of cholesterol synthesis in the whole body [23, 
24] and cell cultures [13].  We reported that gemfibrozil suppresses the production 
of cholesterol through the inhibition of HMG-CoA reductase in cell culture [13, 15], 
but unexpectedly increases it via a remarkable stimulation of peroxisomal and 
microsomal HMG-CoA reductase after oral administration to rats [7, 11].  
Furthermore, we reported that the two agents affect differently the synthesis of 
isoprenoid lipids such as ubiquinone, dolichol and cholesterol in the whole body and 
cultured cells of rats [13, 15, 25]. 
There are three kinds of trophoblasts in the placenta: cytotrophoblasts, 
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syncytiotrophoblasts and extravillous trophoblasts.  Each of the three plays 
important roles in development and the maintenance of gestation.  In human 
trophoblasts, peroxisomes are known to be present in cytotrophoblast cells [20, 22], 
and are detected later during gestation in syncytiotrophoblast cells [22].  Almost all 
cells which produce hormones secrete either steroid hormone or protein hormone, but 
the trophoblast cells secrete both.  Steroid hormone is synthesized from cholesterol.  
Peroxisomes take part in cholesterol synthesis [26].  Sterol carrier protein 2 may 
participate in steroid hormone synthesis [27-29], and is reported to be primarily 
localized in peroxisomes [30-32].  However, less is known about the effect of 
PPARα agonist on hormone synthesis (secretion) [21, 33, 34].  Therefore, we 
studied the effects of gemfibrozil and clofibric acid on the secretion of progesterone 
(steroid hormone) and human chorionic gonadotropin (hCG) (protein hormone) from 
extravillous trophoblast cells, in addition to cell growth and metabolism.  The 
characteristics of immortalized cells are not similar to those of cancer cells, but are 
rather similar to those of normal cells.  Thus, we used an immortalized trophoblast 
cell-line (TCL-1) [35] for the present study. 
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2.  Materials and methods 
 
2.1. Materials 
 
The gemfibrozil used in this study was a gift from Warner-Lambert.   
Clofibric acid, palmitoyl-CoA, leuco-2,7-dichlorofluorescin diacetate (Leuco-DCF), 
o-nitrophenylacetate, NAD, Triton X-100, and fetal calf serum were obtained from 
Sigma.  RPMI 1640 medium was purchased from Nissui Chemicals.  The 
progesterone EIA kit used was from the Cayman Company.  The assay kit for hCG 
was obtained from Wako Pure Chemicals.  All other reagents were of analytical 
grade and were purchased from Wako Pure Chemicals. 
 
 
2.2. Culture of trophoblast cells and drug treatment 
 
The trophoblast cell line-1 (TCL-1) was obtained by immortalizing 
third-trimester human trophoblast with the large-T antigen from the SV40 virus, as 
described in detail elsewhere [35].  The cells in RPMI 1640 medium (12 mL) 
containing 2 mM glutamine, 0.2% gentamycin sulfate, and 10% fetal bovine serum 
(FBS) were plated in plastic plates (100 mm diameter) at 105 cells/mL and then 
cultured at 37°.  The medium was changed 24 hr after plating.  Drug treatment was 
initiated 24 hr after plating by changing the medium to a drug-containing one, and 
thereafter the medium was changed every 24 hr.  Gemfibrozil or clofibric acid 
solubilized in ethanol was added.  The final concentration of ethanol was 0.2% (v/v).   
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Ethanol was also added in the medium of control cells.  In the last 24 hr of the 
culture the medium was collected for the assay of hormone concentrations and lactate 
dehydrogenase activity.  The attached cells were washed with phosphate-buffered 
saline and suspended in 0.25 M sucrose containing 1 mM EDTA and 10 mM 
Tris-HCl (pH 7.4), and cell homogenates were then prepared with a Potter-Elvehjem 
type Teflon homogenizer.  These homogenates were used for the assay of enzyme 
activity and protein content. 
The homogenate was also used for preliminary experiment of cell fractionation.  
The homogenate of control cells was centrifuged at 500 x g for 1 min at 4°, and 
unbroken cells were then removed.  The resulting supernatant was centrifuged at 
10,5000 x g for 1 hr at 4°.  Activity of catalase and fatty acyl-CoA oxidase in the 
particulate and supernatant fractions obtained was assayed. 
 
 
2.3. Assay of enzymes and protein 
 
Fatty acyl-CoA oxidase and catalase are marker enzymes of peroxisomes.  
Fatty acyl-CoA oxidase activity was determined by measuring the H2O2-dependent 
oxidation of leuco-2,7-dichlorofluorescin diacetate (Leuco-DCF) at 502 nm catalyzed 
by exogenous horseradish peroxidase [12, 36].  This spectrophotometric assay has 
been demonstrated to be mUch more sensitive than previous methods of measuring 
peroxisomal fatty acid oxidation [37], due to the large absorption coefficient of the 
dye DCF and the favorable stoichiometry of the peroxidation reaction.  Catalase 
activity was measured according to the method of Leighton et al. [38] with slight 
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modification [39].  Esterase is a marker enzyme of microsomes.  Its activity was 
determined using o-nitrophenyl acetate as a substrate according to Beaufay et al. [40].  
The acid phosphatase activity was determined as a marker enzyme of lysosomes, 
using the method described previously [39].   
Cytotoxity was evaluated by measuring the activity of lactate dehydrogenase in 
the cells and medium and by viewing morphological changes with an inverted 
microscope.  Lactate dehydrogenase activity was measured according to Glascott et 
al. by monitoring the oxidation of NADH at 340 nm in the presence of pyruvate [41]. 
Protein levels were determined by the Lowry method, using BSA as a standard 
[42]. 
 
 
2.4. Assay of hormone concentration 
 
A progesterone EIA kit (Cayman Company) was used to quantitate 
progesterone in the culture medium.  Human chorionic gonadotropin was 
quantitated using a solid phase immUnoassay kit purchased from Wako Pure 
Chemicals. 
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3.  Results 
 
3.1. TCL-1 cells possess functional peroxisomes 
 
Functional peroxisomes in TCL-1 cells were demonstrated by content in active 
peroxisomal marker enzymes (fatty acyl-CoA oxidase and catalase) and their 
recovery (about 80%) in the particulate fraction.  After incubation of TCL-1 cells 
for 3 days, the activity of both enzymes was clearly detectable in the cells, and 
increased dependent on the concentration of cell protein.  Activity levels of the fatty 
acyl-CoA oxidase and catalase of the trophoblast cells was 0.265 mU/mg protein and 
1.35 U/mg protein, respectively.   
 
 
 
3.2.  Clofibric acid and gemfibrozil inhibit cell growth rates in a dose-dependent 
manner  
 
First, we studied the effect of PPARα agonists, clofibric acid and gemfibrozil, 
on the proliferation of the cells.  The immortalized cells were cultured with or 
without the agents for 4 days.  The cells were harvested at the time indicated in Fig. 
1, and the DNA and protein content was then determined.  Figure 1 A (1) shows the 
time courses of the changes in DNA content at various concentrations of the agents.  
The DNA content of control cells gradually increased during incubation for 4 days, 
indicating normal growth of the cells.  Gemfibrozil at not less than 0.25 mM 
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suppressed the rate of increase in DNA content as compared to the control.  
Clofibrate at not less than 2.5 mM clearly lowered the rate.  However, even at the 
highest concentrations of both agents, the DNA content on day 4 was higher than that 
on the first day. 
     Figure 1 A (2) illustrates the effect of the concentrations of the agents on DNA 
content 3 or 4 days after incubation.  All values are relative to the control.  The 
content after treatment with 0.25 and 0.35 mM gemfibrozil for 3 days was about 71.1 
and 57.3 % of the control, respectively.  On the other hand, that after treatment with 
2.5 mM clofibric acid for 3 days was approximately 47.2% of the control.  After 
incubation for 4 days, the DNA content after treatment with 0.25 and 0.35 mM 
gemfibrozil was significantly decreased to about 61.7 and 52.1% of the control, 
respectively.  The content after treatment with 2.5 mM clofibric acid was about 
42.3% of the control.     
Figure 1 B (1) shows the time courses of the changes in protein content at 
various concentrations of the agents.  The protein content of control cells increased 
in a time-dependent manner during 4 days.  As it did the DNA content, gemfibrozil 
at not less than 0.25 mM decreased the rate of increase in protein content as 
compared to the control.  Clofibrate at not less than 2.5 mM clearly decreased the 
rate.   
Figure 1 B (2) illustrates the concentration dependency of gemfibrozil and 
clofibric acid on protein content after incubation for 3 or 4 days.  All values are 
relative to the control.  The content after treatment with 0.25 and 0.35 mM 
gemfibrozil for 3 days was about 70.1 and 66.4 % of the control value, respectively.  
On the other hand, that after treatment with 2.5 mM gemfibrozil for 3 days was about 
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51.2% of the control.  The protein content after treatment with 0.25 and 0.35 mM 
gemfibrozil for 4 days was significantly decreased to about 68.2 and 57.4%, 
respectively.  The content after treatment with 2.5 mM clofibric acid was 
approximately 48.5% of the control.    
 
Fig. 1 
 
     Protein content was decreased at the same concentrations of the agents as DNA 
content.  These results suggest that gemfibrozil and clofibric acid beyond particular 
concentrations suppress the proliferation of immortalized human trophoblast cells.  
Matsuo and Strauss reported that numbers of JEG-3 choriocarcinoma cells which are 
derived from syncytiotrophoblasts were 52% of control values, after 3 days in culture 
in the presence of 3 mM clofibric acid.  The diminished cell number was not due to 
syncytium formation or cell death, as there was no evidence of abnormal cell 
morphology or an increase in cell detachment.  Moreover, the effects were 
reversible, as cell growth returned to normal after removal of the drug [21].  In the 
present study, we used clofibric acid at concentrations lower than 3 mM, and could 
detect neither abnormal cell morphology nor cell death under an inverted microscope.  
Therefore, clofibric acid may suppress the proliferation of immortalized TCL-1 cells 
as it does JEG-3 choliocarcinoma cells. 
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3.3.  Clofibric acid and gemfibrozil affect marker enzyme activities from several 
subcellular compartments  
 
The ability of the fibrate compounds to influence cell metabolism has been 
assessed in TCL-1 cellls by studying drug impact on markers from subcellular 
compartments including peroxisomes (fatty acyl-CoA oxidase and catalase), 
lysosomes (acid phosphatase) and microsomes (esterase).  Figure 2 gives an 
overview of drug-induced changes in marker enzyme activities.  Significant 
drug-induced changes in fatty acyl-CoA oxidase included at the third incubation day 
a 1.53 increase by 0.05 mM gemfibrozil, 1.93 and 1.96 stimulation by 1.0 and 2.5 
mM clofibric acid respectively.  At the incubation 4, the peroxisomal oxidase was 
significantly increased by 0.25 mM clofibric acid.  Significant drug-induced 
changes in catalase included at the third incubation day a 1.23 increase by 0.05 mM 
gemfibrozil, 1.30 and 1.34 stimulation by 0.25 and 1.0 mM clofibric acid respectively.  
The activity of acid phosphatase tended to increase by both agents, but that of 
esterase hardly changed,   
 
Fig. 2 
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3.4.  Clofibric acid and gemfibrozil up-regulate progesterone and down-regulate 
hCG secreted by TCL-1 cells  
 
The ability of gemfibrozil and clofibric acid to affect hormone secretion has 
been assessed in TCL-1 cellls by studying drug impact on progesterone and hCG.  
Significant drug-induced changes in progesterone secretion included at the third 
incubation day a 1.48 increase by 0.25 mM gemfibrozil, 1.75 and 3.04 stimulation by 
1.0 and 2.5 mM clofibric acid respectively.  At the incubation 4, significant 
drug-induced changes in progesterone secretion included 1.62 and 2.4 stimulation by 
1.0 and 2.5 mM clofibric acid respectively (Fig. 3 (1)).  Significant drug-induced 
changes in hCG secretion included at the third incubation day 0.745 and 0.505 
decrease by 0.35 mM gemfibrozil and 2.5 mM clofibric acid, respectively.  At the 
incubation 4, significant drug-induced changes in hCG secretion included 0.762 and 
0.681 decrease by 0.25 and 0.35 mM gemfibrozil, 0.641 and 0.435 inhibition by 1.0 
and 2.5 mM clofibric acid, respectively (Fig. 3 (2)). 
As illustrated in Figure 3 (2), increasing doses of drugs gradually depress 
TCL-1 cell hCG secretion with, at the third incubation day, significant decreases in 
hormone concentration amounting to 25.5% and 49.5% upon 0.35 mM gemfibrozil 
and 2.5 mM clofibrate, respectively.  At incubation day 4, increasing doses of drugs 
depress hCG secretion with, significant decreases in hormone concentration 
amounting to 23.8% and 31.9% upon 0.25 and 0.35 mM gemfibrozil, 35.9% and 
56.5% upon 1.0 mM and 2.5 mM clofibric acid, respectively.  
 
Fig. 3 
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3.5.  Clofibric acid and gemfibrozil depress TCL-1 cell lactate dehydrogenase and 
do not exhibit cytotoxicity  
 
We biochemically studied the cytotoxity of gemfibrozil and clofibric acid in 
trophoblast cells by measuring the activity of a marker enzyme, lactate 
dehydrogenase, in the cells and medium.  As illustrated in Figure 4 (1), increasing 
doses of drugs gradually depress TCL-1 cell lactate dehydrogenase with, at 
incubation day 4, significant decreases in enzyme activity amounting to 31.3% and 
46.6% upon 0.35 mM gemfibrozil and 2.5 mM clofibrate, respectively.  At drug 
dose and incubation day tested, the compounds did not exhibit cytotoxic lysis as 
attested by the absence of significant increases induced in cell media lactate 
dehydrogenase (Figure 4 (2)). 
 
Fig. 4 
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4.  Discussion 
 
Since human extravillous trophoblast cells are difficult to obtain, there are 
fewer reports about these cells than villous trophoblast cells.  Osumi et al. reported 
that rat hepatoma cells become larger by treatment with ciprofibrate [4].  In the 
present study, at the higher concentrations of clofibric acid and gemfibrozil the 
relative amount of protein was suppressed at almost the same rate as the relative 
amount of DNA (Fig. 1).  Therefore, differing from rat hepatoma cells, TCL-1 cells 
treated with the PPARα agonists might not become larger than control cells.   
     In our previous report, the protein content of rat hepatic cells was not decreased 
by the treatment with 0.25 mM gemfibrozil for 3 days [13].  However, the present 
data clearly showed that 0.25 mM gemfibrozil suppresses the proliferation of the cells 
(Fig. 1).  These results suggest that trophoblast cells are more susceptible to 
gemfibrozil than rat hepatic cells. 
Clofibrate is reported to induce apoptosis in cultured human hepatocytes [12].  
Goll et al. reported that apoptosis was easily induced by peroxisome proliferators in 
confluent cells of human hepatic carcinoma cells, HepG2 cells, but not in growing 
cells [14, 16].  Canute et al. reported that apoptosis induced by clofibrate in HepG2 
cells is not connected to the activation of PPARα [43].  Matsuo and Strauss reported 
that clofibric acid suppresses proliferation of JEG-3 choliocarcinoma cells by 
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stimulating p53 (tumor suppressor) expression through PPAR [21].  It is known that 
p53 protein which induces apoptosis also blocks cell cycle progression in the G1 
phase.  Gemfibrozil and clofibric acid probably block cell cycle progression of 
TCL-1 cells by stimulating p53 expression, and suppress the proliferation.  However, 
further study is needed for clarification of this point. 
This is the first report which proposes the existence of peroxisomes in human 
extravillous trophoblast cells.  Fatty acyl-CoA oxidase and catalase activities were 
increased by the treatment with gemfibrozil and clofibric acid (Fig. 2).  In human 
liver cells, some reports indicate an increase in peroxisomal enzyme activity by 
peroxisomal proiliferators [5, 6, 10, 12, 19], but others do not [2, 3, 8, 9, 14].  Our 
data support the former.  However, because of the restricted extent of induction by 
gemfibrozil and clofibric acid, the absolute activation of PPARα  is yet unclear.  In 
the other reports, in order to study the effects of PPARα agonist on peroxisomal 
enzymes in human cells, clofibric acid and/or ciprofibrate were mostly used [2, 3, 5, 
6, 8-10, 12, 14, 19], and so the effect of gemfibrozil was first studied this time.   
It is reported that apoptosis was easily induced by peroxisome proliferators in 
confluent cells of HepG2 cells [16].  In the present study, after incubation for 4 days 
the cell population was nearly confluent.  Therefore, some changes possibly 
occurred in the cells on day 4, and so a significant increase of peroxisome marker 
enzyme activities was rarely detected.  
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The activity of acid phosphatase tended to increase by gemfibrozil and clofibric 
acid (Fig. 2 (3)), but that of esterase hardly changed (Fig. 2 (4)), suggesting that the 
agents somewhat affect lysosomes, but not microsomes.  The increase in 
peroxisome enzyme activities and no change in microsome enzyme activitiy suggest 
that the increase in the specific activity of peroxisome enzymes was not caused by the 
decrease in protein content.  
Matsuo and Strauss reported that the decrease in progesterone secretion by 3 
mM clofibric acid depends on reduced cell growth of JEG-3 cells [21].  In the 
present study, 1 mM clofibric acid did not reduce the cell growth (Fig. 1), but 
increased progesterone secretion (Fig. 3 (1)).  These results indicate that even at 
higher concentrations of the agent, the increase in progesterone secretion is caused by 
the agents.  It was also reported that levels of mRNA encoding the key steroidogenic 
enzyme, cytochrome P450scc, were modestly increased by 3 mM clofibric acid in 
JEG-3 cells [21], indicating that these findings are compatible with our result of the 
increase in progesterone secretion.  
Secretion of hCG was decreased by gemfibrozil and clofibric acid (Fig. 3 (2)).  
Matsuo and Strauss reported that 3 mM clofibric acid suppresses the mRNA 
expression of hCG in JEG-3 cells [21].  The decrease of hCG secretion in TCL-1 
cells may be caused by the same mechanism as in JEG-3 cells.  Maruo et al. 
reported that progesterone selectively suppresses the production and secretion of hCG 
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by normal placenta [44].  The intra-regulatory relationship between steroid and 
protein hormones in the placenta may be also related to the decrease of hCG 
secretion. 
The percent activity of lactate dehydrogenase in the cells was large and 
remained at about 95% even at the highest concentrations of gemfibrozil and clofibric 
acid (Fig. 4), indicating that the increase in progesterone secretion from the cells 
treated with the agents does not depend on cell damage. 
Diseases of peroxisome function including adrenoleukodystrophy and neonatal 
adrenoleukodystrophy, are associated with deficits in steroidogenesis [45].  In 
addition, it is reported that many data pointed out the important role of peroxisomes 
in steroid biosynthesis [46].  We considered a possible mechanistic link between 
peroxisomes and progesterone synthesis as follows.  Peroxisomes participate in fatty 
acid β-oxidation and mevalonate pathway  [47].  Acetyl-CoA derived from 
β-oxidation may be used for cholesterol synthesis in peroxisomes.  Cytochrome 
P450scc is localized in mitochondria and catalyzes the pathway from cholesterol to 
pregnenolone.  Progesterone may be synthesized from pregnenolone in 
mitochondria/microsomes  [48, 49].  Peroxisomal sterol carrier protein 2 may 
participate in the transport of steroid such as cholesterol [27-29].  If somewhere on 
these pathways is stimulated by PPARα agonist, progesterone biosynthesis/secretion 
is possibly increased.   
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In conclusion, PPARα agonists gemfibrozil and clofibric acid inhibit the 
proliferation of trophoblast cells.  Cell metabolism is probably affected by both 
agents.  Gemfibrozil and clofibric acid may enhance the secretion of progesterone 
from the cells, but suppress that of hCG.  Gemfibrozil at lower concentrations than 
clofibric acid affects these cellular functions.  Therefore, immortalized human 
trophoblast cells (TCL-1) seem to be useful for investigating changes in the functions 
of human cells caused by PPARα agonists. 
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 Figure legends 
 
Fig. 1.  Changes in DNA and protein content of human trophoblast cells treated with 
gemfibrozil and clofibric acid.  Drug treatment was initiated 24 hr after plating (12 x 
105 cells/plate) by changing the culture medium to one containing gemfibroｚil or 
clofibric acid, and the medium was then changed every 24 hr.  (1) Time course of 
change in the DNA and protein content.  The cells were harvested at the times 
indicated.  The DNA and protein content of cells was determined as described in the 
text.  Data are mean values of 5 experiments.  (2) Changes in DNA and protein 
content relative to the control after 3 (●) or 4 (○) days of incubation.  The DNA and 
protein content (mg/plate) was expressed as a value relative to the control (0 mM).  
Data are the mean ± SD of 5 experiments.  * indicates significant difference (*, 
p<0.05). 
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Fig. 2.   Effects of gemfibrozil and clofibric acid on enzyme activity of trophoblast 
cells after 3 or 4 days of incubation.  After incubation with various concentrations of 
gemfibrozil and clofibric acid for 3 (●) or 4 (○) days, the cells were harvested.  The 
fatty acyl-CoA oxidase (1), catalase (2), acid phosphatase (3) and esterase (4) activity 
of the cells was measured as described in the text.  The specific activity (u or 
mU/mg protein) was expressed relative to the control (0 mM) at each concentration 
of the agents.  Data are the mean ± SD of 5-7 experiments.  * indicates significant 
difference (*, p<0.05).  The fatty acyl-CoA oxidase activity of control cells at 3 and 
4 days was 0.265 ± 0.138 and 0.282 ± 0.117 mU/mg protein, respectively.  The 
catalase activity of control cells at 3 and 4 days was 1.35 ± 0.35 and 1.79 ± 0.44 
U/mg protein, respectively.  The acid phosphatase activity of control cells at 3 and 4 
days was 16.9 ± 3.5 and 16.7 ± 2.9 mU/mg protein, respectively.  The esterase 
activity of control cells at 3 and 4 days was 71.7 ± 12.8 and 105.3 ± 13.0 U/mg 
protein, respectively. 
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Fig. 3.  Influence of gemfibrozil and clofibric acid on levels of progesterone and 
hCG secreted from trophoblast cells.  After incubation with various concentrations 
of gemfibrozil and clofibric acid for 3 (●) or 4 (○) days, the medium was collected.  
The progesterone (1) and hCG (2) concentration was measured as described in the 
text.  The amounts of progesterone and hCG per protein (pg/mg protein/24 h) were 
expressed as values relative to the control (0 mM) at each concentration of the agents.  
Data are the mean ± SD of 5 experiments.  * indicates significant difference (*, 
p<0.05).  The concentration of progesterone secreted from the control cells at 3 and 
4 days was 85.7 ± 36.3 and 88.3 ± 32.5 pg/mg protein/24 h, respectively.  The 
concentration of hCG secreted from control cells at 3 and 4 days was 16.7 ± 3.8 and 
27.5 ± 5.1 mIU/mg protein/24 h, respectively. 
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Fig. 4.  Cytotoxic effects of gemfibrozil and clofibric acid on trophoblast cells after 
3 or 4 days of incubation.  After incubation with various concentrations of 
gemfibrozil and clofibric acid for 3 (●) or 4 (○) days, the medium and cells were 
harvested.  The lactate dehydrogenase activity of the cells and medium was 
measured as described in the text.  (1) The specific activity (U/mg protein) was 
expressed relative to the control (0 mM) at each concentration of the agents.  Data 
are the mean ± SD of 6 or 7 experiments.  * indicates significant difference (*, 
p<0.05).  The lactate dehydrogenase activity of control cells at 3 and 4 days was 
3.46 ± 1.45 and 4.63 ± 0.97 U/mg protein, respectively.  (2) Effects of gemfibrozil 
and clofibric acid on the percentage of total activity of lactate dehydrogenase in the 
trophoblast cells and in the medium.  Opened bars show the percentage of enzyme 
activity in the cells, and closed bars show that in the medium. 
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